New hope for hard-to-treat leukemia? early trial tests eganelisib alone and with chemo.
Disease control
Recruiting now
This early-phase study tests a new drug called eganelisib, given alone or with standard chemotherapy (cytarabine), in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have returned or not responded to prior treatments. The main goals are …
Phase: PHASE1 • Sponsor: Stelexis BioSciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC